Abbott Laboratories (BVMF:ABTT34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 824.27B -36.4% |
| Revenue (ttm) | 235.45B +6.6% |
| Net Income | 32.61B -53.5% |
| EPS | 18.62 -53.6% |
| Shares Out | n/a |
| PE Ratio | 25.27 |
| Forward PE | 16.20 |
| Dividend | 0.68 (1.73%) |
| Ex-Dividend Date | Apr 14, 2026 |
| Volume | 105 |
| Open | 38.80 |
| Previous Close | 38.91 |
| Day's Range | 38.80 - 39.68 |
| 52-Week Range | 33.50 - 64.06 |
| Beta | 0.62 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 15, 2026 |
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, h... [Read more]
Financial Performance
In 2025, Abbott Laboratories's revenue was $44.33 billion, an increase of 5.67% compared to the previous year's $41.95 billion. Earnings were $6.50 billion, a decrease of -51.49%.
Financial numbers in USD Financial StatementsNews
New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers
Study at ADA's Scientific Sessions shows participants in Abbott's Healthy Food Rx program combined with health coaching had significant health improvements Abbott's Healthy Food Rx program is a Food i...
Abbott announces new data on DKA for people with Type 1, Type 2 diabetes
Abbott (ABT) announced new data revealing diabetic ketoacidosis, DKA, “remains an important, yet often undetected health concern for people living with both Type 1 and Type 2 diabetes,” the company…
New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
Diabetic ketoacidosis (DKA) can develop quickly and is not always easy to detect early Ketone monitoring is not yet routine in diabetes care, which may contribute to missed warning signs of DKA and de...
Abbott Labs must face lawsuit over PediaSure children's growth claims
Abbott Laboratories must defend against a proposed class-action lawsuit claiming it misled consumers into believing its PediaSure Grow & Gain nutrition drinks were "clinically proven" to help childre...
MiniMed announces expanded ketone sensor agreement with Abbott
MiniMed (MMED) announced an expanded agreement with Abbott (ABT) to collaborate on commercializing dual glucose-ketone sensors designed to integrate exclusively with MiniMed smart dosing systems. Thes...
Abbott secures CE Mark for Libre Duo, Libre Duo 10 Day
Abbott (ABT) announced it has secured CE Mark for the world’s first dual glucose-ketone sensing technology for people with diabetes. Branded as Libre Duo and Libre Duo 10 Day, the…
Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes
First-of-its-kind biowearables combine continuous glucose and ketone monitoring in a single sensor to support both daily diabetes management and help detect rising ketone levels that can lead to diabe...
ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
Cologuard® and Cologuard Plus® reaffirmed as preferred options for noninvasive colorectal cancer (CRC) screening in updated American Cancer Society guideline Abbott to offer only CRC screening portfol...
Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026
Data highlight how screening and diagnostics enable earlier detection, more precise treatment decisions, and improved patient outcomes from risk to remission New MRD data from the PARTNER study demons...
3 ‘Strong Buy’ Dividend Aristocrat Stocks with 15%+ Upside, 5/22/26
Walmart ($WMT), Abbott Laboratories ($ABT), and NextEra Energy ($NEE) are the three dividend aristocrat stocks with a Strong Buy rating on Wall Street and payout ratios of more than 50%,…
3 ‘Strong Buy’ Dividend Aristocrat Stocks with 100%+ Payout Ratios, 5/14/26
The article uses TipRanks’ Dividend Aristocrat tool to identify AbbVie ($ABBV), Abbott Laboratories ($ABT), and NextEra Energy ($NEE) as three dividend aristocrat stocks with a Strong Buy rating on Wa...
Abbott receives FDA clearance and CE Mark for next-generation Ultreon™ 3.0 AI-powered coronary imaging platform
Ultreon 3.0 is the first advanced optical coherence tomography (OCT) system in the U.S. and Europe that integrates high resolution coronary plaque images and AI-automated insights through the artery T...
Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026
Four late-breaking presentations at Heart Rhythm Society 2026 in Chicago highlight strong clinical evidence across Abbott's growing pulsed field ablation and novel cardiac pacing portfolios Six-month ...
New data at AACR 2026 demonstrate advancements in Cancerguard® Multi-Cancer Early Detection Test
Data show how a multi-biomarker class approach improves early-stage cancer detection AACR will also recognize landmark DETECT-A study publication reporting long-term outcomes supporting the clinical i...
Abbott Laboratories Cuts Outlook, Says Mild Flu Season Hurt Sales
Abbott Laboratories cut its full-year earnings outlook to account for a recent acquisition and said a weaker-than-expected flu season hurt its recent quarter.
Abbott Laboratories Earnings Call Transcript: Q1 2026
Q1 results met expectations with 3.7% sales growth and $1.15 adjusted EPS, despite higher financing costs and a weak respiratory season. The Exact Sciences acquisition is integrating well, driving growth in cancer diagnostics, while medical devices and pharma segments delivered strong performances.
Abbott Laboratories Earnings release: Q1 2026
Abbott Laboratories released its Q1 2026 earnings on April 16, 2026, summarizing the period's financial results.
Abbott Laboratories Slides: Q1 2026
Abbott Laboratories has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 16, 2026.
Abbott Laboratories Quarterly report: Q1 2026
Abbott Laboratories has published its Q1 2026 quarterly earnings report on April 16, 2026.
Abbott Stock Tumbles on Earnings. Nutrition Business Is Struggling and Merger Costs Are Biting.
Abbott Laboratories continues to grapple with falling sales in its nutrition segment.
Abbott first-quarter results beat on cancer diagnostics, medical device strength
Abbott marginally beat Wall Street estimates for quarterly profit and revenue on Thursday, partially helped by its newly acquired cancer diagnostics business.
Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences
First-quarter GAAP diluted EPS of $0.61; adjusted diluted EPS of $1.15 reflects growth of 6 percent Completed acquisition of Exact Sciences, establishing Abbott as a leader in the fast-growing oncolog...
Jury orders Abbott to pay $53 million in preterm infant formula trial, media report says
A jury in Chicago on Thursday said Abbott Laboratories must pay $53 million in compensatory damages to a group of families that had accused the company of failing to warn that its formula for prematur...